Kiora Pharmaceuticals (KPRX) Change in Receivables (2024 - 2026)
Kiora Pharmaceuticals' (KPRX) quarterly Change in Receivables came in at $21483.0 in Q1 2026, down 97.08% YoY from $736407.0 in Q1 2025, and down 93.06% on a QoQ basis from $309544.0 in Q4 2025.
Kiora Pharmaceuticals (KPRX) Change in Receivables (2024 - 2026) Analysis & Trends
Kiora Pharmaceuticals (KPRX) has 3 years of Change in Receivables data on file, last reported at $21483.0 in Q1 2026.
- Quarterly Change in Receivables fell 97.08% year-over-year to $21483.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $206649.0 (down 81.99% YoY) and the FY2025 annual result came in at $921573.0, up 53.29% from the prior year.
- Change in Receivables declined to $21483.0 in Q1 2026, from $309544.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $1.2 million in Q2 2024 to a low of -$1.2 million in Q3 2025.
- A 3-year average of $171583.7 and a median of $309544.0 in 2025 frame the typical range for Change in Receivables.
- The widest YoY moves for Change in Receivables: up 287.78% in 2025, down 372.47% in 2025.
- Tracing KPRX's Change in Receivables over 3 years: stood at -$1.2 million in 2024, then surged by 126.18% to $309544.0 in 2025, then tumbled by 93.06% to $21483.0 in 2026.
- The last three Change in Receivables figures came in at $21483.0 (Q1 2026), $309544.0 (Q4 2025), and -$1.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Kiora Pharmaceuticals | 15.64 Mn | 15.64 Mn | - | -452,867.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -452,867.00 |
| Jun 30, 2026 | -452,867.00 |
| Mar 31, 2026 | 21,483.00 |
| Mar 31, 2026 | 21,483.00 |
| Dec 31, 2025 | 309,544.00 |
| Dec 31, 2025 | 309,544.00 |
| Sep 30, 2025 | -1.20 Mn |
| Sep 30, 2025 | -1.20 Mn |
| Jun 30, 2025 | 1.08 Mn |
| Jun 30, 2025 | 1.08 Mn |
| Mar 31, 2025 | 736,407.00 |
| Mar 31, 2025 | 736,407.00 |
| Dec 31, 2024 | -1.18 Mn |
| Dec 31, 2024 | -1.18 Mn |
| Sep 30, 2024 | 442,175.00 |
| Sep 30, 2024 | 442,175.00 |
| Jun 30, 2024 | 1.15 Mn |
| Jun 30, 2024 | 1.15 Mn |
| Mar 31, 2024 | 189,904.00 |
| Mar 31, 2024 | 189,904.00 |